Reversible agranulocytosis associated with oral terbinafine in a pediatric patient

Journal of the American Academy of Dermatology

Volumn 45, Issue 4, 2001, Pages 632-634

  Aguilar, Christopher ^a   Mueller, Kurt K ^b  

^a Naval Hospital Beaufort   (United States)

^b GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENICILLIN G; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TERBINAFINE;

ADOLESCENT; AGRANULOCYTOSIS; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; CASE REPORT; DISEASE ASSOCIATION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; MALE; NAIL DISEASE; ONYCHOMYCOSIS; PRIORITY JOURNAL; TINEA PEDIS; TOE MALFORMATION;

EID: 0034804356     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2001.117520     Document Type: Article

References (10)

1. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial
2. Terbinafine: An update
3. Neutropenia and pancytopenia associated with oral terbinafine
4. Reversible agranulocytosis associated with oral terbinafine for onychomycosis
5. Thrombocytopenia associated with oral terbinafine
6. Severe neutropenia associated with oral terbinafine therapy
7. An open study of tinea capitis in 50 children treated with a 2-week course of oral terbinafine
8. Pilot study of terbinafine in children suffering from tinea capitis: Evaluation of efficacy, safety and pharmacokinetics
9. Terbinafine-induced neutropenia
10. Antifungal therapy in children